(WT) counterparts and independent of histologic grade. [2] [3] [4] [5] Grade IV gliomas that have acquired IDH1 or IDH2 (IDH) mutations have a median overall survival of 31 months as compared with 15 months for those with WT IDH. 2 Among high-grade gliomas, patients with IDH-WT grade III tumors also exhibit worse prognosis than those with IDH-mutated grade IV tumors. 6 The IDH gene product normally converts isocitrate into α-ketoglutarate, while mutations in the IDH gene family result in enzyme products that instead drive conversion of isocitrate into 2-hydroxyglutarate (2-HG). 2-HG competitively inhibits downstream histone demethylases, which contributes to abnormal regulation of gene expression in these cancers. 7 At present, the most commonly used method for assessing IDH mutation status is immunohistochemical analysis following biopsy or surgical resection. Multiple exome sequencing studies have demonstrated, however, that up to 15% of IDH-mutated gliomas are not detected by traditional IDH1 (p.R132H) antibody testing. 8, 9 In addition, while biopsy for most intracranial masses can be performed with relatively low risk, a noninvasive method for preoperative prediction may be helpful for operative planning; a recent study suggested that subtotal resection of enhancing tumor was associated with longer overall survival in IDH-WT highgrade glioma, whereas only complete resection including both enhancing and nonenhancing components of tumor improved survival in IDH-mutated gliomas. 10 It is these aspects of IDH-WT and IDH-mutated high-grade glioma that increase the impetus for preoperative determination of IDH genotype with methods such as MRI.
Genomic alterations in gliomas are associated with a number of radiographic features on MRI. 11 Several of these standard imaging features including unilateral growth, tumor margin sharpness, and signal intensity heterogeneity vary significantly with IDH genotype and prognosis, although these associations have largely been based on univariate analyses. 12, 13 Single imaging features are expected to perform less well in predicting IDH genotype in HHGs as a result of greater tumor heterogeneity. 14, 15 Studies correlating the genetic and clinical features of glioma based on qualitative imaging analysis such as degree of enhancement and appearance of tumor margins are prone to interrater variability. 16 In recent years, machine-learning algorithms have been applied to imaging studies of gliomas to predict genotype and patient survival outcomes based on imaging features extracted from conventional MRI. [17] [18] [19] [20] In this study, we retrospectively examined the preoperative MRI of 120 patients diagnosed with either primary grade III or IV glioma with known IDH genotype. We hypothesized that a model integrating multimodal MRI features using a machine-learning approach could accurately predict IDH genotype in HGGs.
Methods

Patient Enrollment
This study was conducted following approval by the DanaFarber/Brigham and Women's Cancer Center (DF/BWCC) Institutional Review Board (IRB). MR imaging, clinical variables including primary patient demographics (ie, age, sex, KPS, and preoperative steroid use), and genotyping data were obtained from the medical record under a consented research protocol approved by the DF/BWCC IRB (11-104). We retrospectively identified patients who met the following criteria: (i) histopathologically confirmed primary grade III or IV glioma according to current WHO criteria, 21 (ii) known IDH genotype, and (iii) available preoperative MRI consisting of precontrast axial T1-weighted (T1), postcontrast axial T1-weighted (T1c), axial T2-weighted fast spin echo (FSE, T2), T2-weighted fluid attenuation inversion recovery (T2/FLAIR) images, and MR-diffusion weighted imaging (DWI). Patients with secondary HGGs were excluded from this study. Patients whose genetic data were not confirmed per criteria (see "Tissue Diagnosis and Genotyping" section below) and whose tumors did not demonstrate contrast enhancement were excluded. Our final cohort included 120 patients with primary grade III (n = 35) and grade IV (n = 85) gliomas.
Tissue Diagnosis and Genotyping
All sequencing assays were performed within the Molecular Diagnostics Division of the Brigham and Women's Hospital Center for Advanced Molecular Diagnostics, a CLIAcertified laboratory environment. IDH1/2 mutations were determined using immunohistochemistry, 22 mass spectrometry-based mutation genotyping (OncoMap), 22, 23 or multiplex exome sequencing (OncoPanel) 8, 24 depending on which genotyping technologies were available at the time of diagnosis. For this retrospective study, only gliomas with absence of IDH1/2 mutations as determined by full sequencing assay with OncoPanel, were included in our analyses as IDH-WT gliomas. IDH-mutated gliomas were defined by the presence of mutation as indicated by immunohistochemistry or either of the 2 sequencing methods.
Briefly, diaminobenzidine (DAB) brightfield staining was performed according to standard protocols on 5-micron thick paraffin sections. Antigens were retrieved using heat and 10 mM sodium citrate buffer (pH 6.0), and the following primary antibody was utilized: IDH1(R132H) (Dianova, DIA-H05). Counterstaining for nuclei was performed using Mayer's hematoxylin stain, and coverslips were mounted with Permount (Fisher Scientific). OncoMap is a multiplexed Sequenom-based assay to detect somatic mutations in tumor DNA and was performed in the DF/BWCC CLIA-certified laboratory. OncoMap v4 detects mutations in 471 different loci from 41 cancer genes. OncoPanel (Illumina HiSeq) is a DNA-based next-generation sequencing assay that detects somatic mutations in 275 different cancer genes including IDH1 and IDH2.
MRI Data Acquisition and Preprocessing
Standard MR imaging protocol for brain tumors at our institution includes nonenhanced sagittal and axial T1-weighted imaging, axial T2-weighted FSE and T2/FLAIR imaging, contrast-enhanced axial T1-weighted imaging, and 3D spoiled gradient echo (SPGR) imaging with coronal and sagittal reconstructions. Gadopentetate dimeglumine
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(Magnevist, Bayer Healthcare) was administered for contrast-enhanced imaging.
MR-DWI images were acquired before injection of contrast and were obtained with TE/TR 80-110 ms/4-10 s, section thickness 5 mm with 1 mm intersection gap, matrix size 128 × 128, and FOV 22-25 cm by using monopolar spin-echo echo-planar preparation. Apparent diffusion coefficient (ADC) images were calculated from acquired DWI with b-values of 0 s/mm 2 and 1000 s/mm 2 images. ADC maps were generated using Advantage Workstation (version 4.3, GE Healthcare). All MR images were transferred to a high-performance cluster server for post processing. 25 Volumetric Tumor Segmentation Figure 1 provides an overview of our MRI processing pipeline. The computer-based Brain Tumor Image Analysis (BraTumIA, version 1.2) software was used to co-register and skull-strip T1, T1c, T2, and T2/FLAIR images. The segmentation protocol was completed as described previously. 26 Briefly, whole tumor volume, which includes solid tumor, infiltrating tumor, and edema, were segmented from FLAIR imaging. The T1c images from MRI were used for enhancing-tumor volume segmentation. Enhancingtumor volume was subtracted from whole tumor volume to obtain the nonenhancing tumor volume. 3D Slicer Software (version 4.1), a user-driven manual active contour segmentation tool, was used to segment tumor volumes. 27, 28 The segmented volume contour was overlaid with source T1c and T2/FLAIR images and edited by the study neuroradiologist (R.Y.H.) to manually add pixels for tumor regions not included in the preliminary contour or remove pixels for nontumor regions included in the preliminary contour.
Generation of Subregional Volume Mask
Additional volumes were calculated within whole tumor, enhanced tumor, and nonenhanced tumor volume segmentations. Regions with ADC values <1100 and 1350 × 10 −6 mm 2 /s were segmented. In addition, to characterize tumor margins, edge submasks were calculated by detecting the edge of whole tumor and enhanced tumor volumes, then width dilations to lengths of 5 voxels outside and 3 voxels inside this edge. The resulting edge submasks have an 8 voxel width that captures regions of both tumor and normal-appearing brain.
MRI Feature Extraction
For each glioma case, we extracted 5 categories of features (anatomical location, shape, texture, multimodal voxel parametric, and histogram) from volume masks and submasks to maximize the characterization of the tumor.
Anatomical features were defined by the study radiologist (R.Y.H.) by region (frontal, temporal, parietal, occipital, and deep brain) and laterality (left, right). The remaining shape, texture, multimodal parametric features, and ADC features were calculated from MRI (Supplemental Materials Section).
Classification Procedure
The machine-learning procedure was performed using the Statistics and Machine Learning Toolbox MATLAB 2015a. We applied the random forest algorithm to generate a model predictive of IDH genotype. Random forest is one of several machine-learning algorithms that have been applied in clinical classification problems. It is especially advantageous when the number of predictor variables greatly exceeds sample size because it is resistant to overfitting. 29 This method has been applied successfully for identifying single-nucleotide polymorphisms among millions of mutations in known DNA repair pathways that may contribute to the development of grade IV glioma. 30 This approach can also distinguish low-grade from high-grade gliomas by MRI features from area under the receiver operating characteristic (AUROC) analysis. 31 Building a classifier involved growing multiple decision trees based on random selection of predictors (ie, MRI features) and random selection of data (ie, glioma cases). In this study, all 120 patients were randomly assigned to either the training cohort (n = 90) or validation cohort (n = 30). All cases in the training cohort were used to train the classifier, while cases in the validation cohort were used to independently evaluate the performance of the final model.
In implementing the random forest algorithm, we specified 3 parameters: (i) the number of features used during the training process, (ii) the maximum depth of the trees, and (iii) the number of trees grown. The predictive value of each MRI feature for determining IDH genotype was calculated individually by AUROC analysis. Features with AUC values >0.7 were then isolated and ranked. Redundant features, which were defined as features with a Spearman rank correlation coefficient >0.7, P < .05 with another feature of higher AUC, were removed. The remaining 386 features were used in our training algorithm. The tree depth was set to 64, and the algorithm was set to grow to a total of 4096 trees, a number empirically determined to be a reasonable upper bound in our learning models and before which the training set classification error commonly begins to converge. 32 Individual trees were grown by taking a bootstrap sample from the training cohort with a fixed boot fraction of one-half. For each tree, growth at each branch utilized all 386 MRI features, and bootstrapped cases were used to grow the tree while the remaining out-of-bag cases were used as the test set. The random forest algorithm integrated all decorrelated trees to create a final classifier. Ten-fold cross validation was also applied to calculate misclassification error of our model within the training cohort. Finally, the model was tested on the validation cohort using the same model score threshold selected based on AUROC analysis of the training set. Subgroup analyses were also performed to test the final model on grade III and grade IV gliomas individually.
Features with most significant contributions to the final model were determined by the increase in prediction error if the values of that feature were permuted across the outof-bag observations. This measure was computed for every tree and then averaged over the entire ensemble and divided by the standard deviation over the entire ensemble. 33 
Statistical Analysis
All statistical analyses were performed using the Statistics and Machine Learning Toolbox 2015a (MATLAB). For comparison of mean model score between IDH-WT and -mutated high-grade gliomas, the Student t test was used with significance defined as <0.05.
Results
Patient Characteristics
MRI images were obtained from 120 patients with primary grade III (n = 35, 17 male [49%], age range 23y-72y) and grade IV (n = 85, 35 male [41%], age range 21y-85y) gliomas. IDH mutations were identified in 32 of 35 (91%) grade III gliomas and in 22 of 85 (26%) grade IV gliomas. One grade IV tumor harbored an IDH2 mutation; all other IDH-mutated tumors had IDH1 mutations. The proportion of IDH-mutated tumors in our grade IV cohort was higher than usual due to exclusion of IDH-WT gliomas that did not have sequencing data to confirm genotype. IDH1 and IDH2 mutations were mutually exclusive in our cohort, consistent with previous reports. 34, 35 As such, IDH1-and IDH2-mutated gliomas were collapsed into one category. Each glioma was then randomly assigned to either the training or validation cohort in the learning model ( Table 1) .
Because of the retrospective nature of this study, KPS at the time of imaging was unfortunately unavailable for our cohort. Data on steroid use at the time of imaging were available for 91 patients (53 IDH-WT, 38 IDH-mutated); 9% (5/53) of patients with IDH-WT gliomas had initiated treatment prior to imaging, while 34% (13/38) patients with IDHmutated tumors had initiated steroid use prior to imaging. Incorporating steroid use as a feature in our model did not significantly improve IDH prediction.
MRI Features and Univariate Analyses
From each patient's imaging, 2970 features were extracted. A total of 386 features remained after removing redundant features. The nonredundant features included 14 anatomical location, 27 shape, 114 texture, 212 parametric intensity, and 19 histogram features.
We also evaluated individual MRI features, which were previously associated with IDH status, for their predictive 
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value in determining IDH genotype within our cohort. 12, 13, 36 The univariable AUCs for these MRI features tested on all 120 glioma were as follows (listed in order from least to most predictive): frontal or temporal tumor location (AUC = 0.5051), ADC (AUC = 0.5098), laterality (AUC = 0.5185), and T2/FLAIR volume (AUC = 0.6758).
Genotype Prediction
IDH genotype prediction using our model achieved accuracies of 86% (AUC = 0.8830) in the training cohort and 89% (AUC = 0.9231) in the validation cohort (Fig. 2) . The mean predictive model scores for WT and mutant gliomas were 0.36 (95% confidence interval [CI], 0.30-0.41) and 0.59 (95% CI, 0.52-0.65), respectively (P < .0001) (Fig. 3) . The training set classification error based on 10-fold cross validation was 0.1667. The 10 features that contributed most to our model are shown in Table 2 . Patient age was the most important feature in our classifier; the relationship between age and IDH genotype is depicted in Fig. 3 . To assess the impact of MRI features alone, we generated a model excluding age and sex; this model achieved predic- 
Discussion
In this study, a random forest classifier was created to integrate clinical data with multimodal, preoperative imaging features to predict IDH genotype in high-grade gliomas. Our model achieved 86% accuracy in the training cohort and 89% prediction accuracy in the validation cohort. This model only relied on patient age and imaging features extracted from a standard, preoperative MRI protocol including conventional T1, T2, and diffusion weighted imaging. 40 To date, IDH prediction in a combined cohort of grades III and IV has not been attempted. Such a study may be of clinical importance given that IDH genotype may be a more useful prognostic marker than WHO grade; patients with IDH-WT grade III tumors have been shown to exhibit worse prognosis than those with IDH-mutated grade IV tumors. 6 Here, machine learning enabled the integration of clinical data with quantitative, multimodal imaging features to build a model predictive of IDH genotype in a combined grade III and IV glioma cohort.
The features that contributed most to IDH genotype prediction in our model included age and MRI parametric intensity, texture, and shape features. Not surprisingly, patient age was the most important feature in our model, reflecting the observation that patients with IDH-mutated glioma present at a significantly younger age than those with IDH-WT tumors. 41, 42 Of note, one other clinical feature (ie, steroid use) yielded a significant finding: more patients with IDH-WT tumors than IDH-mutated tumors had initiated steroid treatment at the time of preoperative imaging. This difference has not been reported previously and could be explored on other datasets. While steroid treatment has been shown to affect the appearance of tumors by reducing contrast permeability and peritumoral edema, 20, 37, 38 including this feature in our model did not improve IDH prediction. The remaining top 10 features contributing to IDH prediction were MRI features, and 8 among them were obtained by filtering tumor volumes using ADC thresholds rather than the whole tumor volumes. The utility of DWI in glioma prognostication has been demonstrated previously 20, 26, 43, 44 ; we corroborated the utility of DWI to subselect volumes of interests with greater contribution to our model performance.
Several multimodal texture and parametric intensity features also contributed highly to our predictive model, although the underlying biological mechanism for how these features relate to IDH mutation is presently unclear. Past studies in glioma have correlated IDH genotype with intratumoral heterogeneity as well as with tumor margins based on qualitative assessment of conventional MRI. 12, 13 Both texture and parametric intensity features extracted from MRI in our study may provide quantitative measures of such tissue heterogeneity within the tumor as well as along tumor margins. In addition, the textural features used in our model have been previously applied to distinguish gliomas based on MGMT promoter methylation status. 45, 46 Brown et al. also found that texture features could be used to predict 1p/19q co-deletion in low-grade gliomas, 47 and Liu et al. observed associations between texture features and p53 and MIB-1 genotype. 48 While we tested our combined features model in predicting IDH genotype, we also evaluated the predictive value of individual MRI features. No individual MRI feature achieved greater accuracy in predicting IDH genotype than the Abbreviations: ADC, apparent diffusion coefficient; AUC, area under the curve: FLAIR, fluid-attenuated inversion recovery. a Information measure of correlation, compactness, and inverse correlation are texture features that have been previously applied to classify gliomas by degree of malignancy 54 and to predict survival outcomes in grade IV gliomas. 55 Detailed equations for these texture features are described elsewhere. 55, 56 NeuroOncology combined model. This observation underscores the advantage of using a machine-learning algorithm to discover and integrate synergistic multimodal imaging features.
We also examined MRI features previously identified to vary with IDH genotype: frontoinsular-temporal tumor location, laterality, T2/FLAIR volume, and ADC. 12, 13, 36, 39 Among these features, only T2/FLAIR volume (AUC = 0.6758) achieved an AUC >0.6. While T2/FLAIR volume was removed as a redundant feature in our pipeline, an associated feature (ie, contrast-enhancing tumor to T2/FLAIR volume) did contribute to our combined model. This finding concurs with previous studies that have broadly evaluated contrast enhancement and T2/FLAIR in IDH-mutated gliomas. Qi et al. correlated the extent of contrast enhancement with IDH1 genotype in grade III gliomas, 12 while Carrillo et al. identified an association between the presence of noncontrast-enhancing tumor and IDH1 mutation in grade IV gliomas. 49 MRI parameters combining contrast enhancement with nonenhancing perilesional FLAIR hyperintensity have also been reported to predict IDH1 mutation in grade IV gliomas. 50 Recent studies have also suggested that MR spectroscopy is a promising noninvasive technique for identifying IDH-mutated gliomas through detection of intratumoral 2-HG. [51] [52] [53] Perfusion imaging features such as measures of tumor blood flow may also be of added value in IDH genotype prediction. 40 Our multimodality model may be improved by the addition of these imaging features in the future. Improvements in IDH prediction, however, would have to be balanced with the added complexity of obtaining MR spectroscopy and perfusion imaging (not currently part of standard imaging protocol) when optimizing for clinical utility. The features utilized in the current model are extracted from conventional MRI only.
There are several other important limitations to our study. Few IDH-WT grade III gliomas (n = 3) were included in these analyses due to strict eligibility requirements for both genetic and MRI data. All IDH-WT gliomas in our cohort had sequencing data to avoid inclusion of tumors with IDH mutations not detected by immunochemistry. Our model was also generated based on single-institution, retrospectively collected data, and its generalizability depends on feature stability that can be impacted by differences in imaging acquisition protocols as well as the reproducibility of image postprocessing and tumor segmentation. Our model needs, therefore, to be further validated using independent data. In addition, while a large number of imaging features have been incorporated into our model, our machine-learning approach did not provide the biological significance of individual features and how they interact with each other. Further work is needed to characterize and refine these features to potentially improve model performance. Finally, the processing time required to generate our model may also be a limitation to its clinical adoption, but hopefully this can be reduced with availability of validated, automated tumor segmentation algorithms.
The current study used machine-learning algorithms to generate a model that predicted IDH genotype in highgrade gliomas based on patient age as well as quantitative imaging features derived from standard, preoperative MRI. Our model achieved an accuracy of 89% in the validation cohort and may have the potential to serve as a noninvasive tool that provides important prognostic information and aids operative planning.
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